Dataset from A Multicenter, Randomized, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of Insuman Comb 25 (Insulin Human) Versus Novolin® 30R Twice Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus Who Are Under Insulin Therapy
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00007734
下载链接
链接失效反馈官方服务：
资源简介：
Primary Objective:
To compare the efficacy of Insuman Comb 25 versus Novolin® 30R on HbA1c reduction during a
24-week treatment period in patients with type 2 diabetes mellitus.
Secondary Objectives:
- To assess the effects of Insuman Comb 25 versus Novolin® 30R in patients with type 2
diabetes mellitus on fasting plasma glucose (FPG)
- To assess the safety and tolerability of Insuman Comb 25 versus Novolin® 30R in patients
with type 2 diabetes mellitus
创建时间：
2024-11-26
